Metraipolis › archive › dc_01e77de77fdd

Visualized clinical-radiomics model for predicting the efficacy of surufatinib in hepatic metastases of neuroendocrine neoplasms — Europe PMC PMID:40951355

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/40951355
DOI
10.3389/fonc.2025.1628054
License (as archived)
solo-consultazione
Archived
2026-11-10T06:53:48.709Z
SHA-256 of the archived text
9f02b7d65a9bc6c92309e4509940ae54444bcf639eb6686bb207e2d77706803d
Stable URL of this page
https://metraipolis.com/documento/dc_01e77de77fdd

How to cite

Visualized clinical-radiomics model for predicting the efficacy of surufatinib in hepatic metastases of neuroendocrine neoplasms — Europe PMC PMID:40951355 — Europe PMC (en), https://europepmc.org/article/MED/40951355 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_01e77de77fdd (Metraipolis archive dc_01e77de77fdd, sha256 9f02b7d65a9bc6c92309e4509940ae54444bcf639eb6686bb207e2d77706803d)
BibTeX
@misc{dc01e77de77fdd,
  title = {Visualized clinical-radiomics model for predicting the efficacy of surufatinib in hepatic metastases of neuroendocrine neoplasms — Europe PMC PMID:40951355},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/40951355},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_01e77de77fdd; sha256 9f02b7d65a9bc6c92309e4509940ae54444bcf639eb6686bb207e2d77706803d},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/40951355. Agents can read the archived copy with the MCP tool read_document.